2-TUR QANDLI DIABETI MAVJUD BEMORLARDA SURUNKALI BUYRAKLAR KASALLIGINING KECHISHIGA SGLT2 INGIBITORLARIDAN EMPAGLIFLOZINLAR, DAPAGLIFLOZINLAR VA KANAGLIFLOZINLAR TA'SIRINING TAQQOSLAMA TAHLILINI O’RGANISH.
Keywords:
2-tur qandli diabet, surunkali buyrak kasalligi, SGLT2-ingibitorlari, empagliflozin, dapagliflozin, albuminuriyaAbstract
Ushbu tadqiqot 2-tur qandli diabet (QD) bilan og‘rigan bemorlarda surunkali buyrak kasalligi (SBK) kechishiga SGLT2-ingibitorlari
(empagliflozin, dapagliflozin, kanagliflozin) ning ta’sirini o‘rganish va ularning samaradorligini taqqoslashga qaratilgan.
References
1. American Diabetes Association (ADA). (2023). Diabetes Care Guidelines.
2. Heerspink, H. J., et al. (2020). SGLT2 inhibitors and kidney protection: A meta
analysis. Lancet, 395(10224), 753-762.
3. Perkovic, V., et al. (2019). Canagliflozin and Renal Outcomes in Type 2 Diabetes
and CKD. NEJM, 380(24), 2295-2306.
4. Bakris, G. L., Agarwal, R., Anker, S. D., et al. (2021). Empagliflozin SBK va yurak
yetishmovchiligida: EMPA-KIDNEY tadqiqoti natijalari. The Lancet Diabetes &
Endocrinology, 9(7), 461-474.
5. Zinman, B., Wanner, C., Lachin, J. M., et al. (2022). SGLT2-ingibitorlarining yurak
qon tomir va buyrak funktsiyasiga ta’siri: Klinik tadqiqotlar sharhi. Diabetes Care,
45(3), 529-541.